Ischemic Stroke - Pipeline Insight, 2024

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $2,500	180 Pages	DelveInsight	August, 2024	DEL19082426

Best Price Guarantee
Price	from $2,500
Length	180 Pages
Publisher	DelveInsight
Published Date	August, 2024
SKU	DEL19082426

Ischemic Stroke - Pipeline Insight, 2024

DelveInsight’s, “Ischemic Stroke - Pipeline Insight, 2024” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Ischemic Stroke pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Ischemic Stroke: Understanding

Ischemic Stroke: Overview

Stroke is a leading cause of death and disability worldwide and can be broadly classified into ischemic stroke and haemorrhagic stroke, the latter of which includes intracerebral haemorrhage and subarachnoid haemorrhage. Ischemic stroke is defined as infarction of the brain, spinal cord or retina1 and represents ~71% of all strokes globally. Advances in brain imaging have shifted the definition of ischemic stroke from a largely clinical determination to a tissue-based classification. Many transient events with full clinical recovery are now classed as stroke based on the identification of permanent tissue injury on MRI. A transient ischemic attack (TIA or mini-stroke) is the same as a stroke but the symptoms only last for a short amount of time. It is a major warning sign of a stroke and should always be taken seriously.

The etiology of ischemic stroke is due to either a thrombotic or embolic event that causes a decrease in blood flow to the brain. In a thrombotic event, the blood flow to the brain is obstructed within the blood vessel due to dysfunction within the vessel itself, usually secondary to atherosclerotic disease, arterial dissection, fibromuscular dysplasia, or inflammatory condition. In an embolic event, debris from elsewhere in the body blocks blood flow through the affected vessel. The etiology of stroke affects both prognosis and outcomes.

For the diagnosis, blood tests may be used to check your overall health. The blood's ability to clot will also be tested. Blood tests may include a check for diabetes. Diabetes increases the risk for a stroke. CT or MRI pictures may show where the stroke happened and any damage to the brain. Additionally, an arteriography is used to take x-rays of your arteries to look for blood flow blockage.

Current optimal management of patients with ischemic stroke occurs in geographically defined stroke units with an experienced interdisciplinary team of physicians, nurses and allied health clinicians, using best-evidence stroke guidelines, which includes intravenous thrombolysis and/or endovascular thrombectomy. Intravenous thrombolysis reduces disability when administered within 4.5h of stroke onset (defined as the time from when the patient with a stroke was last known to be healthy)6 , although selected patients with favorable brain perfusion imaging benefit up to 9 h or after wake-up-onset stroke (that is, stroke symptoms upon waking that were not present before sleep).

""Ischemic Stroke- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ischemic Stroke pipeline landscape is provided which includes the disease overview and Ischemic Stroke treatment guidelines. The assessment part of the report embraces, in depth Ischemic Stroke commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ischemic Stroke collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Ischemic Stroke R&D. The therapies under development are focused on novel approaches to treat/improve Ischemic Stroke.

Ischemic Stroke Emerging Drugs Chapters

This segment of the Ischemic Stroke report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Ischemic Stroke Emerging Drugs

Nelonemdaz: GNT Pharma

Nelonemdaz, previously known as Neu2000, is a derivative of aspirin and sulfasalazine and is a multitarget neuroprotective agent with potent inhibitory effects against Ca2+ permeability of the NMDA (N-methyl-D-aspartate) receptor. Nelonemdaz is a multitarget neuroprotectant that selectively blocks N-methyl-D-aspartate receptors and scavenges free radicals, as proven in preclinical ischemia-reperfusion studies. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Ischemic Stroke.

3K3A-APC: ZZ Biotech

ZZ Biotech LLC is developing 3K3A-APC, a newly designed, modified, recombinant activated protein C (APC) pharmaceutical for the treatment of acute ischemic stroke. 3K3A-APC is derived from a 461-residue protein C zymogen precursor expressed via recombinant technology in Chinese Hamster Ovary (CHO) cells. Its amino acid sequence differs from that of the wild-type human Activated Protein C (APC). Currently, the drug is in the Phase III stage of development to treat Ischemic Stroke.

JX10: JIXING Pharmaceuticals

JX10 (formerly BIIB131) is an investigational drug developed by Ji Xing Pharmaceuticals, formerly by Biogen, for the treatment of acute ischemic stroke (AIS). It is proposed to have both thrombolytic and anti-inflammatory activities, aiming to restore critical blood flow post-stroke and potentially improve clinical outcomes for AIS patients. Currently, the drug is in the Phase II stage of development to treat Ischemic Stroke.

Elezanumab: AbbVie

Elezanumab (ABT-555) is a monoclonal antibody RGMa inhibitor being investigated by AbbVie to treat spinal cord injuries and acute ischemic stroke. RGMa is a potent modulator of axonal growth, myelination, and downstream immunoregulatory molecules (eg, interlukin‐10 [IL‐10]) that are important factors for inhibiting neuronal and oligodendroglial regeneration and functional recovery after central nervous system (CNS) trauma or inflammation. RGMa neutralization is a novel approach that may provide neurorestoration/regeneration and functional recovery in a variety of degenerative CNS diseases. It is currently in Phase II of clinical inverstigation for the treatment of AIS (Acute Ischemic Stroke).

UMC119-06: Meridigen Biotech Co., Ltd.

Meridigen has been developing UMC119-06, an umbilical cord-derived MSCs (hUC-MSCs) drug. Focusing on the potential and multiple therapeutic effects of UMC119-06 including anti-oxidation, immunomodulation, lung cell protection and, anti-fibrosis. Currently, the drug is in the Phase I stage of development to treat Ischemic Stroke.

Further product details are provided in the report……..

Ischemic Stroke: Therapeutic Assessment

This segment of the report provides insights about the different Ischemic Stroke drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Ischemic Stroke
There are approx. 50+ key companies which are developing the therapies for Ischemic Stroke. The companies which have their Ischemic Stroke drug candidates in the most advanced stage, i.e. Phase III include, GNT Pharma and ZZ Biotech.
Phases

DelveInsight’s report covers around 55+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Ischemic Stroke pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical
Molecule Type

Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Ischemic Stroke: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Ischemic Stroke therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ischemic Stroke drugs.

Ischemic Stroke Report Insights

Ischemic Stroke Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs

Ischemic Stroke Report Assessment

Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Ischemic Stroke drugs?
How many Ischemic Stroke drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ischemic Stroke?
What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Ischemic Stroke therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Ischemic Stroke and their status?
What are the key designations that have been granted to the emerging drugs?